BioSpace News Archive

Quantitative Scientific Solutions (“QS-2”), a leading provider of scientific and technical consulting and data analytics services, today announced that it has joined the DNA Data Storage Alliance to further the mission of creating and promoting a novel archival storage ecosystem based on DNA to meet the challenges posed by the explosive growth of digital data.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will release first quarter 2021 operating results after the close of the market on Monday, May 10, 2021.

Core One Labs Inc. is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs.

Avacta Group plc is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group’s recently developed SARS-CoV-2 research ELISA Affimer® reagents.

ANI Pharmaceuticals, Inc. announced that it has acquired the new drug applications for OXISTAT® Lotion, VEREGEN® Ointment, and Pandel® Cream and the abbreviated new drug application for ApexiCon® E Cream from Sandoz Inc. Pandel® Cream will be transitioned later upon receiving the requisite approvals.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide for the treatment of COVID-19 related gastrointestinal infections.

NeuroRx, Inc. reports that Aviptadil, to be supplied by NeuroRx, has been identified by the National Institutes of Health as one of two drugs selected for inclusion in a phase III multicenter clinical trial that will include the United States and multiple foreign countries.

Phase 1 clinical study investigates safety and tolerability, pharmacokinetics and pharmacodynamic effects of first-in-class azasugar AZ-3102 in healthy subjects

Opthea Limited advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer of the Company, with effect 24 June 2021.

VLA2001, an inactivated COVID-19 vaccine candidate with CpG 1018 adjuvant, was highly immunogenic and generally safe and well tolerated